Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.32 |
| ▸ | GFER | P55789 | 1/20 | 0.32 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.32 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5447257 | 1.00 | KMT2A (0.40) | KMT2AMEN1CYP19A1ALDH1A1PDE4B | |
| SCHEMBL5447249 | 1.00 | KMT2A (0.40) | KMT2AMEN1CYP19A1ALDH1A1PDE4B | |
| SCHEMBL5187528 | 0.84 | MEN1 (0.54) | KMT2AMEN1ALDH1A1 | |
| SCHEMBL21748812 | 0.84 | MEN1 (0.54) | KMT2AMEN1ALDH1A1GAA | |
| SCHEMBL21748813 | 0.84 | MEN1 (0.54) | KMT2AMEN1ALDH1A1GAA | |
| SCHEMBL5187522 | 0.84 | MEN1 (0.54) | KMT2AMEN1ALDH1A1 | |
| SCHEMBL21748809 | 0.84 | MEN1 (0.54) | KMT2AMEN1ALDH1A1GAA | |
| SCHEMBL5446034 | 0.84 | MEN1 (0.40) | KMT2AMEN1PDE4B | |
| SCHEMBL5446044 | 0.84 | MEN1 (0.40) | KMT2AMEN1PDE4B | |
| SCHEMBL5446039 | 0.84 | MEN1 (0.40) | KMT2AMEN1PDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070270471-A1 | Compounds Which Potentiate Glutamate Receptor and Uses Thereof in Medicine | GLAXO GROUP LIMITED (GB) | 2007-11-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070270471-A1 | Compounds Which Potentiate Glutamate Receptor and Uses Thereof in Medicine | GRM3, GLRA3, GLRA1 | KMT2A 1913/4885MEN1 2794/4885CYP19A1 2019/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.